HomeEverythingEducationTV
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Tempus AI to acquire cancer test maker Personalis for $1.5 billion

Created at 20 Jul · 12:51 PM2 sources↑ Market-relevant2 events
IN SHORT

Tempus AI announced its intention to acquire Personalis for approximately $1.5 billion. The deal aims to integrate Personalis' cancer test into Tempus AI's oncology portfolio, enhancing its precision medicine platform.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

$1.5 billionacquisition price for Personalis
$16.25per share price for Personalis shareholders

Who's Involved

Tempus AI
Company acquiring Personalis
Personalis
Cancer test maker being acquired by Tempus AI

↳ Why This Matters

The acquisition aims to bolster Tempus AI's precision medicine capabilities in oncology by integrating Personalis's cancer testing technology, potentially leading to advancements in cancer diagnosis and treatment.

Key facts

  • Tempus AI will acquire Personalis for approximately $1.5 billion.
  • The acquisition aims to integrate Personalis' cancer test into Tempus AI's oncology portfolio.
  • Personalis shareholders will receive $16.25 per share, with a mix of stock and potential cash payment.

Tempus AI has announced its intention to acquire Personalis for approximately $1.5 billion. The strategic move is designed to incorporate Personalis' cancer testing capabilities into Tempus AI's oncology portfolio, enhancing its AI-enabled precision medicine platform. Personalis shareholders are set to receive $16.25 per share, with the payment structured primarily in Tempus stock, though Tempus retains the option to cover up to half of the transaction in cash.

Frequently asked questions

Tempus AI is acquiring Personalis for approximately $1.5 billion.

The acquisition aims to integrate Personalis' cancer test into Tempus AI's oncology portfolio, enhancing its AI-enabled precision medicine capabilities.

Personalis shareholders will receive $16.25 per share, primarily in Tempus stock, with Tempus having the option to pay up to 50% in cash.

What Happens Next

01The acquisition is expected to close.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

Tempus AI will acquire Personalis for approximately $1.5 billion.
The acquisition aims to integrate Personalis' cancer test into Tempus AI's oncology portfolio.
Personalis shareholders will receive $16.25 per share, primarily in Tempus stock, with Tempus holding the option to pay up to 50% in cash.

Sources

T1
Tempus to acquire Personalis for $1.5 billionReuters
T1
Tempus to buy cancer test maker Personalis for $1.5 billionPiQSuite

Related Stories

Cardinal Health to acquire AdaptHealth diabetes unit, Strive Medical for $360 million
20 Jul · 9:27 PM
Philippine Airlines orders 15 Boeing 787s
20 Jul · 12:58 PM
Judge Halts Paramount-Warner Bros. Merger Talks Amid Antitrust Lawsuit
20 Jul · 5:26 PM
Primark to cut prices by up to 29% ahead of AB Foods demerger
20 Jul · 9:26 AM
Lockheed Martin unveils cheaper Patriot interceptor amid soaring air defense demand
20 Jul · 6:07 AM